Anyone in NNOS? Now at .195. Has held well through latest market downturn. I think it might be ready to move up. Here is some news from today.
Thursday February 26, 11:04 am ET
LAS VEGAS--(BUSINESS WIRE)--Feb. 26, 2004--NanoSignal Corp. (OTC BB: NNOS - News) Chief Executive Scott A. Ervin announced today the opening of a sales office in Bombay, India. The sales force will be under the direction of Dr. Vivian DeSouza who will began calling on the numerous hospitals and clinics in a country of more than 1 billion residents. "We are very excited to explore this emerging market for SLICES(TM) technology. We expect significant interest from local representatives in the medical and sales community," said Ervin.
To summarize recent developments, NanoSignal recently announced a definitive agreement with Dr. Jeffery Taft, to provide technical and scientific consultation. Taft is a veteran of the early days of the company when it was known as MicroSignal. With Taft's addition to the team, NanoSignal is ready to pursue new applications of its technology -- most notably early detection of stroke. Cerebral blood flow and coronary artery blood flow are potential areas that show great promise using NanoSignal's proprietary technology.
NanoSignal recently announced that it had entered into a consulting agreement with Al Noshirvani to develop sales and marketing of SLICES(TM). Noshirvani comes to NanoSignal with a wealth of sales and marketing experience having been a sales professional in the medical equipment and health industries for more than 10 years. Noshirvani will help NanoSignal establish a national distribution network for SLICES(TM) and will implement a best business practices marketing program. Noshirvani has scheduled a SLICES(TM) sales and marketing seminar for March 2004 in Las Vegas with further details to be announced.
NanoSignal announced recently that Felicia Browell had been hired to design a professional user manual for SLICES(TM). Browell will consult with Taft and the engineering team. Browell will assist NanoSignal in creating comprehensive documentation that should make SLICES(TM) become recognized as the No. 1 leader in user-friendly software products for the MRI industry.
Ervin stated, "The company is continuing its negotiations with multiple investment banking firms to meet its anticipated funding needs for national and international sales and marketing for the 2004-2005 period. Further details on this subject will be announced when warranted.
"We continue to receive shareholder worksheets from the private shareholders of MicroSignal PA after the Feb. 17 cut-off date with a number of shareholders' notices that went out via registered mail being returned. We are in the process of updating mailing addresses, since over the last several years a number of shareholders have changed addresses without letting the company know their whereabouts. A number of MicroSignal PA shareholders failed to execute the second page of the mailout, as requested. These delays will result in a two-stage distribution to shareholders of MicroSignal PA, with the first group of shares distributed to shareholders who have completed all of the necessary paperwork. We will provide additional details on our corporate Web site as to the exchange of share certificates for those shareholders not in compliance. Any missing shareholders or shareholders against whom there are conflicting claims will be subject to an interpleader action if necessary. We have been working around the clock to get this job accomplished," stated Ervin.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements, and changing price and market conditions. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statement.
Additional information regarding SLICES(TM) and NanoSignal Corp. is available at www.nanosignalcorp.com.
--------------------------------------------------------------------------------
Contact:
Princeton Research Inc.
Michael King, 702-650-3000
